Michael S Stringer

List of Publications by Year
in descending order

19 papers	374 citations	1162367 8 h-index	887659 17 g-index
25 all docs	25 docs citations	25 times ranked	421 citing authors

#	Article	IF	Citations
1	Intracranial hemodynamic relationships in patients with cerebral small vessel disease. Neurology, 2020, 94, e2258-e2269.	1.5	86
2	Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review. Frontiers in Physiology, 2021, 12, 643468.	1.3	65
3	Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. EClinicalMedicine, 2019, 11, 34-43.	3.2	36
4	Sex Differences in Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 756887.	1.1	29
5	Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination. International Journal of Stroke, 2018, 13, 530-538.	2.9	22
6	Sources of systematic error in DCEâ€MRI estimation of lowâ€level bloodâ€brain barrier leakage. Magnetic Resonance in Medicine, 2021, 86, 1888-1903.	1.9	21
7	A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. Translational Stroke Research, 2021, 12, 15-30.	2.3	18
8	Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. European Stroke Journal, 2021, 6, 81-88.	2.7	17
9	Prevalence and Significance of the Vessel-Cluster Sign on Susceptibility-Weighted Imaging in Patients With Severe Small Vessel Disease. Neurology, 2022, 99, .	1.5	11
10	Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial. Stroke, 2022, 53, 29-33.	1.0	10
11	A Comparison of CVR Magnitude and Delay Assessed at 1.5 and 3T in Patients With Cerebral Small Vessel Disease. Frontiers in Physiology, 2021, 12, 644837.	1.3	9
12	Zooming in on cerebral small vessel function in small vessel diseases with 7T MRI: Rationale and design of the â€œZOOM@SVDsâ€•study. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100013.	0.4	8
13	Imaging neurovascular, endothelial and structural integrity in preparation to treat small vessel diseases. The INVESTIGATE-SVDs study protocol. Part of the SVDs@Target project. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100020.	0.4	8
14	Tracer kinetic assessment of bloodâ€“brain barrier leakage and blood volume in cerebral small vessel disease: Associations with disease burden and vascular risk factors. NeuroImage: Clinical, 2021, 32, 102883.	1.4	7
15	Loss of the heterogeneous expression of flippase ATP11B leads to cerebral small vessel disease in a normotensive rat model. Acta Neuropathologica, 2022, 144, 283-303.	3.9	7
16	Relationship between inferior frontal sulcal hyperintensities on brain MRI, ageing and cerebral small vessel disease. Neurobiology of Aging, 2021, 106, 130-138.	1.5	5
17	A Framework for Jointly Assessing and Reducing Imaging Artefacts Automatically Using Texture Analysis and Total Variation Optimisation for Improving Perivascular Spaces Quantification in Brain Magnetic Resonance Imaging. Communications in Computer and Information Science, 2020, , 171-183.	0.4	4
18	Selective Motion Artefact Reduction via Radiomics and k-space Reconstruction for Improving Perivascular Space Quantification in Brain Magnetic Resonance Imaging. Lecture Notes in Computer Science, 2021, , 151-164.	1.0	1

#	Article	IF	Citations
19	Brain hyperintensities in magnetic resonance imaging of patients with mild acute focal neurology. Neurological Sciences, 2020, 41, 1633-1635.	0.9	0